Shanghai MicroPort MedBot (Group) (SEHK:2252) - Share price, News & Analysis

2252 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

2252 Stock Overview

Shanghai Microport Medbot (Group) Co., Ltd.

Rewards

Revenue is forecast to grow 129.58% per year

Risk Analysis

Earnings are forecast to decline by an average of 22% per year for the next 3 years

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue (CN¥2M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shanghai MicroPort MedBot (Group) Competitors

MicroPort Scientific

SEHK:853

HK$33.0b

Angelalign Technology

SEHK:6699

HK$24.4b

Shanghai Bio-heart Biological Technology

SEHK:2185

HK$16.6b

LifeTech Scientific

SEHK:1302

HK$11.0b

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai MicroPort MedBot (Group)
Historical stock prices
Current Share Price	HK$29.85
52 Week High	HK$73.45
52 Week Low	HK$19.92
Beta	0
1 Month Change	-14.10%
3 Month Change	23.86%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-34.83%

Recent News & Updates

May 19

We're Not Very Worried About Shanghai MicroPort MedBot (Group)'s (HKG:2252) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	2252	HK Medical Equipment	HK Market
7D	-15.6%	-3.5%	1.5%
1Y	n/a	-53.8%	-20.8%

Return vs Industry: Insufficient data to determine how 2252 performed against the Hong Kong Medical Equipment industry.

Return vs Market: Insufficient data to determine how 2252 performed against the Hong Kong Market.

Price Volatility

Is 2252's price volatile compared to industry and market?
2252 volatility
2252 Average Weekly Movement	14.0%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.5%
10% most volatile stocks in HK Market	12.8%
10% least volatile stocks in HK Market	3.2%

Stable Share Price: 2252 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: 2252's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

Founded	Employees	CEO	Website
2014	898	Chao He	https://www.medbotsurgical.com

Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People’s Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR’obot, a Mona Lisa robotic transperineal prostate biopsy system.

Shanghai MicroPort MedBot (Group) Fundamentals Summary

How do Shanghai MicroPort MedBot (Group)'s earnings and revenue compare to its market cap?
2252 fundamental statistics
Market Cap	HK$27.85b
Earnings (TTM)	-HK$674.24m
Revenue (TTM)	HK$2.49m

Over9,999x

P/S Ratio

-42.4x

P/E Ratio

Is 2252 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
2252 income statement (TTM)
Revenue	CN¥2.15m
Cost of Revenue	CN¥1.23m
Gross Profit	CN¥919.00k
Other Expenses	CN¥583.84m
Earnings	-CN¥582.92m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 26, 2022

Earnings per share (EPS)	-0.61
Gross Margin	42.74%
Net Profit Margin	-27,112.60%
Debt/Equity Ratio	0.01%

How did 2252 perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is 2252 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2252?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 2252. This is calculated by dividing 2252's market cap by their current preferred multiple.
What is 2252's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CN¥24.08b

2252 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10339.6x
Enterprise Value/EBITDA	-39.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 2252's PB Ratio compare to its peers?

2252 PB Ratio vs Peers

The above table shows the PB ratio for 2252 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	7.1x
853 MicroPort Scientific	2.8x	13.9%	HK$33.0b
6699 Angelalign Technology	6x	21.7%	HK$24.4b
2185 Shanghai Bio-heart Biological Technology	15.4x	n/a	HK$16.6b
1302 LifeTech Scientific	3.7x	n/a	HK$11.0b
2252 Shanghai MicroPort MedBot (Group)	10.3x	-22.0%	HK$27.8b

Price-To-Book vs Peers: 2252 is expensive based on its Price-To-Book Ratio (10.3x) compared to the peer average (7.1x).

Price to Earnings Ratio vs Industry

How does 2252's PE Ratio compare vs other companies in the HK Medical Equipment Industry?

Price-To-Book vs Industry: 2252 is expensive based on its Price-To-Book Ratio (10.3x) compared to the Hong Kong Medical Equipment industry average (1.5x)

Price to Book Ratio vs Fair Ratio

What is 2252's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2252 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	10.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2252's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 2252 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2252's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2252's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Shanghai MicroPort MedBot (Group) forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-22.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2252 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2252 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2252 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2252's revenue (129.6% per year) is forecast to grow faster than the Hong Kong market (10% per year).

High Growth Revenue: 2252's revenue (129.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2252 is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Shanghai MicroPort MedBot (Group) performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-187.3%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 2252 is currently unprofitable.

Growing Profit Margin: 2252 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2252's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2252's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2252 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).

Return on Equity

High ROE: 2252 has a negative Return on Equity (-24.45%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Shanghai MicroPort MedBot (Group)'s financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 2252's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥234.5M).

Long Term Liabilities: 2252's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥167.3M).

Debt to Equity History and Analysis

Debt Level: 2252 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 2252's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2252 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2252 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 93.7% each year.

Discover healthy companies

Dividend

What is Shanghai MicroPort MedBot (Group) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2252's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2252's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2252's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2252's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2252 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure

CEO

Chao He (37 yo)

1.67yrs

Tenure

CN¥32,398,000

Compensation

Dr. Chao He is President and Executive Director of Shanghai Microport Medbot (Group) Co., Ltd. since December 2020 and since October 18, 2017. Dr. He joined the Group in May 2015.Prior to joining our Grou...

CEO Compensation Analysis

Compensation vs Market: Chao's total compensation ($USD4.78M) is above average for companies of similar size in the Hong Kong market ($USD468.92K).

Compensation vs Earnings: Chao's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: 2252's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: 2252's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: 2252 only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/08/18 00:00
End of Day Share Price	2022/08/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31